Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter - Wednesday, October 8, 2025
Stock Region Penny Picks Watchlist Newsletter - Wednesday, October 8, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This newsletter is for informational and entertainment purposes only. The content provided is based on publicly available information and represents our personal opinions. It is not financial advice. Investing in stocks, especially the ones we discuss, carries significant risk. Please do your own research and consult with a licensed financial advisor before making any investment decisions. We may or may not hold positions in the stocks mentioned.
Good morning, Stock Region!
What a day it’s been. The market is a wild place, and today’s news cycle is proving it once again. We’ve got a mix of groundbreaking science, AI buzz, and corporate shake-ups. Let’s break down what’s moving and what you should have on your radar.
The Watchlist
$ATON - The Future of Pharma Funding?
Okay, this one is a mind-bender. ATON just announced a letter of intent to tokenize the economics for one of its cancer treatments. In simple terms, they’re exploring using digital assets (think crypto-style tokens) to fund a specific drug’s development. This is a fascinating, almost sci-fi concept. If they pull this off, it could completely change how biotech companies raise capital. It’s a huge “if,” but the ambition alone makes $ATON a must-watch. This is either genius or madness, and I’m here for the ride to find out which.
$HOWL - A Glimmer of Hope in Cancer Treatment
HOWL received Fast Track Designation from the FDA for its melanoma treatment, WTX-124. This is a big deal. Fast Track is designed to get promising drugs for serious conditions to patients faster. It doesn’t guarantee approval, but it’s a massive vote of confidence from the FDA. This news adds serious legitimacy to their pipeline. For patients, it’s hope. for investors, it’s a sign that HOWL is on the right path. Keep a close eye on this one.
$RNAZ - A Power Move in Oncology
TransCode just made a splash with a double-whammy announcement. They’re acquiring Polynoma and securing a hefty $25 million in strategic financing. This move aims to create a powerhouse in immuno-oncology focused on preventing metastasis (cancer spread). This isn’t just a small step; it’s a giant leap. They’re consolidating power, getting a cash infusion, and sharpening their focus. This could be a transformative moment for the company.
$NXL - A Breakthrough for Alzheimer’s?
Nexalin announced more positive results for its Gen-2 device in treating Alzheimer’s. Any positive news in the Alzheimer’s space is significant, given how many failures we’ve seen. While it’s still early, consistent positive data is exactly what you want to see. This neurostimulation technology is an interesting approach, and if it continues to prove effective, $NXL could be sitting on something truly revolutionary. Cautious optimism is the name of the game here.
The AI Craze Continues: $PUBM, $HOTH, and $TNMG
The AI narrative is on fire, and NVIDIA is fanning the flames.
$PUBM: PubMatic is leveraging NVIDIA’s tech to supercharge programmatic advertising. It’s a smart, practical application of AI that could give them a serious edge in a competitive industry.
$HOTH: Hoth Therapeutics is also jumping on the NVIDIA train, using its AI platform to accelerate drug development. This shows they’re serious about using cutting-edge tools to get ahead.
$TNMG: TNL Mediagene is hosting an entire event on “Next-Gen AI Agents.” This tells me they want to be seen as thought leaders in the space, not just users of the technology.
The takeaway? AI isn’t just a buzzword for these companies; it’s becoming a core part of their strategy. The NVIDIA connection is the common thread, but each is using it to carve out its own niche.
$SCWO - A Shake-Up at the Top
And for our dose of corporate drama, SCWO has appointed an interim CEO and President. “Interim” is the key word here. It signals change and uncertainty. Sometimes, a new leader, even a temporary one, can inject new energy into a company. Other times, it’s a sign of deeper issues. The market will be watching Stephen Jones’s first moves very closely to figure out which it is.
That’s the rundown for today. It’s a market of stories, and some of these are just getting to the exciting chapters. Stay sharp, do your homework, and be ready for whatever comes next.
Final Disclaimer: Remember, investing is risky. The stocks mentioned here are volatile and subject to market swings. Never invest more than you are willing to lose. This newsletter is not a recommendation to buy or sell any security. All investment decisions are your own.